Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4161 聿新科. Please read: https://finlab.finance/en/setup?stock=4161

No install, open FinLab Studio

4161

聿新科 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 聿新科 to your watchlist to track signal changes on your next visit.
Valuation 62Quality 55Growth 89Momentum 17Chips 50

Is 聿新科 a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 61th market percentile. Latest quarterly ROE ≈ 1.8%.

  • Valuation is neutral.PE is in the 41th market percentile; within its own history, PE is around the 11th percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 0.4% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 73.8%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.58
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 第一金-高雄 holds 289 lots
  • sellers have 26 lots left, ~45 sessions to clear

Window from 2026-01-17 · Price -13% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 第一金-高雄 has accumulated 289 lots since the start (sold 0%), still adding.
  • Main distributor 美林 peaked at 30 lots, has sold 60%, 12 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.79pp, mid holders +2, retail -1.28pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -173 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
第一金-高雄玉山-桃園華南永昌-三重永豐金-北高雄元大-古亭康和-台南
Distributing
美林台新-台中元富-世貿永豐金-市政華南永昌-鳳山凱基-三重
Desks
own scale
元大-天母凱基-台北兆豐-來福第一金-台南
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 第一金-高雄 +289
    sold 0%· still adding
  • 玉山-桃園 +284
    sold 0%
  • 華南永昌-三重 +153
    sold 0%· still adding
  • 永豐金-北高雄 +116
    sold 0%
  • 元大-古亭 +110
    sold 0%· still adding
  • 康和-台南 +103
    sold 0%

Distributing

  • 美林 12 left
    sold 60%· paused recently
  • 台新-台中 3 left
    sold 86%· ~2 sessions to clear
  • 元富-世貿 8 left
    sold 58%· paused recently
  • 永豐金-市政 3 left
    sold 80%· ~3 sessions to clear
  • 華南永昌-鳳山 5 left
    sold 62%· paused recently
  • 凱基-三重 9 left
    sold 31%· ~45 sessions to clear

Desks

  • 元大-天母 -173
    unclassified
  • 凱基-台北 -168
    day-trade · selling pressure
  • 兆豐-來福 -128
    unclassified
  • 第一金-台南 -127
    unclassified
Still selling 26 lots ~45 sessions to bottom at most
Recent buy/sell force +232 absorbed / -44 sold buyers slightly ahead
Hedge-desk net short -5 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 73.81%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

59 historical occurrences (since 2013-06-26)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 41.5%, Sample 53, Median -0.6%, Excess +0.21%, Beat mkt rate 32.1%；60-day: Win 42.3%, Sample 52, Median -1.31%, Excess +0.6%, Beat mkt rate 36.5%；120-day: Win 43.1%, Sample 51, Median -4.39%, Excess +1.32%, Beat mkt rate 37.3%

120 days after: historical avg +8.18%

20-day +0.83%
60-day +4.52%
120-day +8.18%
20-day
60-day
120-day
Win
41.5%
42.3%
43.1%
Sample
53
52
51
Median
-0.6%
-1.31%
-4.39%
Excess
+0.21%
+0.6%
+1.32%
Beat mkt rate
32.1%
36.5%
37.3%

Over 51 occurrences, 120-day forward avg gained 8.18%, beat the market by 1.32 pts; win rate 43.1%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 You are here684+1.1% -4% 38.5% -29.5%
20-40 326+16.4% +5.9% 61.3% -24.2%
40-60 2Insufficient data
60-80 61-27.2% -24.4% 0% -64%
80-100 338-28.7% -38.1% 16.9% -46.5%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 18.63, at the 10.9th percentile of its own history (0-20 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+0.9%
Win rate 38.3% Excess -13%
470d
+17.4%
Win rate 96% Excess +4.7%
50d
-18.9%
Win rate 0% Excess -41.9%
183d
60-day momentum down
Now
+3.7%
Win rate 56.9% Excess -7.9%
515d
-1.9%
Win rate 39.2% Excess -13.9%
97d
-17.2%
Win rate 2.8% Excess -41.9%
216d

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum down”: across 515 historical days, 120-day forward avg gained 3.7%, win rate 56.9%, lagged the market by 7.9%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

6 times historically; 60-day forward avg -9.57%, win rate 16.7%, beating the market by -13.05 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

27 times historically; 60-day forward avg -0.5%, win rate 38.5%, beating the market by -2.32 pts on average.

What does 聿新科 do? Company profile

生技醫療業；居家醫療檢測、醫材、保健食品與保養品 櫃買中心上櫃

Overview

4161 對應證券為聿新生物科技股份有限公司，簡稱聿新科，為櫃買中心上櫃普通股，非 ETF、ETN、權證或特別股。公司成立於 1999/06/01，股票於 2013/06/26 上櫃，總部位於苗栗縣竹南鎮公館里中華南路188號。公開股市資料顯示資本額約新台幣5.98億元、發行股數約59,808,204股；部分較舊資料仍列資本額約5.29億元，推估係後續股票股利或限制員工權利新股造成差異。經營團隊方面，官方網站經營團隊頁仍列楊金昌博士為董事長/總經理；2026年股市資料則列董事長楊金昌、總經理涂耀仁，故總經理資訊存在來源更新差異。公司據點包含苗栗竹南總公司、新竹科學園區分公司及台南新市廠；苗栗廠偏居家醫療檢測產品，新竹廠偏保養品與保健食品，台南廠偏蝦紅素及機能原料。員工規模參考 104 人力銀行約180人。2026/05 董監持股資料顯示董事持股約7,911張、占13.23%，內部人持股約9,136張、占15.28%；主要董事持股包含楊金昌約2,290張、葉月琴約1,750張、蔡麗絲約1,098張等。另鉅亨網資料顯示楊金昌另透過新健康資產股份有限公司持有約2,200張，應視為董事長關係人持股。

Business

公司核心為電化學生物感測技術與多功能居家檢測平台，主要產品包含血糖、尿酸、膽固醇、血紅素、血酮、三酸甘油脂等單功能、二合一、三合一、四合一、五合一及七功能監測系統，以及檢測試紙。自有品牌包含 EasyMate 易美測、EasyTouch 易立測、EasySure 易立速，並同時承接 ODM/OEM。官方網站表示旗下 2合1、3合1、5合1 機款通過歐盟認證、外銷70餘國，取得多張 TFDA 醫材許可證。第二事業線為醫材、保養品與保健食品：醫材包括水性傷口敷料與疤痕護理凝膠；保養品以 ACUREAL 艾可麗及 ODM/OEM 為主，產品含化妝水、精華液、乳液、乳霜、面膜、清潔用品等；保健食品包含膠原蛋白、玻尿酸、蝦紅素、美妍飲、葉黃素、益生菌等，並提供飲品、果凍、粉劑、錠劑、膠囊等劑型代工。MoneyDJ 資料顯示 2024 年營收比重約為醫療檢測產品73%，醫材、保養品、保健食品27%；銷售地區比重約台灣78%、歐洲8%、亞洲4%、非洲1%。商業模式為自有品牌銷售、經銷代理、醫材與保健保養品 OEM/ODM、以及部分產品驗證與委託試驗服務。終端應用聚焦三高族群、糖尿病與代謝疾病居家監測、藥局/醫療院所、海外新興市場居家健康管理、保健食品與美容保養品品牌客戶。

Outlook 2025–2028

2025至2028年展望以居家健康管理、慢性病監測、預防醫療、銀髮健康及保健食品需求為主軸。成長動能包括：一、全球糖尿病、三高、痛風、高血脂等慢性病族群增加，推升家用血糖與多功能檢測儀、檢測試片的長期消耗需求；二、公司持續推進多參數檢測，已開發五功能與七功能監測系統，並朝低血量、低侵入、聯網雲端紀錄與快篩產品線延伸；三、2024年研發寵物血糖機，將醫材技術延伸至寵物醫療保健；四、保健食品、蝦紅素、玻尿酸與美容保養 ODM/OEM 可受惠大健康與品牌代工需求；五、2026年前5個月累計營收約3.85億元、年增約24.88%，其中2026年5月營收約9,598萬元、年增73.81%，公司公告備註為訂單增加，顯示短期接單回溫。主要挑戰包括：一、血糖監測市場國際大廠 Roche、Abbott、LifeScan 等品牌強勢，且連續血糖監測 CGM 技術快速滲透，可能壓縮傳統 BGM 與試片成長空間；二、醫材法規、TFDA/CE/FDA 認證與各國通路准入時間長；三、銀漿、碳漿、酵素、電子零組件、包材等成本與匯率波動會影響毛利；四、公司規模較小，單一客戶、區域或訂單遞延可能造成月營收波動；五、保健食品與保養品市場競爭激烈，品牌與通路投入未必立即反映獲利。2027至2028年的具體財測未見公司正式公開，因此僅能以產業趨勢與公司產品路線推估。

Supply Chain

Upstream
  • 銀漿、碳漿、酵素、試紙瓶、測試儀構件、採血筆、軟管、彩盒與化學原料供應商 年報與 MoneyDJ 整理揭露為主要原物料類別，但未確認具名供應商；其中銀漿/碳漿用於檢測試片，化學原料用於天然蝦紅素與保健保養產品。
  • 威旺航太生醫股份有限公司 聿新科子公司，未上市，主要從事天然蝦紅素研發與製造，可視為集團內機能原料來源與研發製造平台。
  • 聿健生物科技股份有限公司 聿新科子公司，未上市，主要從事農業生技、保健食品相關研究與生產。
  • 廣東聿新生物科技股份有限公司 集團關係企業，非台股掛牌，主要與化妝品製造、銷售及進出口貿易相關。
Downstream
  • 海外醫材經銷商與代理商 公司自有品牌與代工產品外銷歐洲、美洲、東南亞等市場，官方稱外銷70餘國；具名客戶多未公開。
  • 台灣藥局、醫療院所與居家健康管理通路 多功能血糖監測系統、檢測試紙、保健食品與保養品的終端通路；多數通路或客戶未具名公開。
  • 麗揚生技股份有限公司 歷史資料顯示曾為化妝保養品總代理商，未上市；2016年前後代理關係已有變動，列為歷史下游關係。
  • 設計家國際有限公司 MoneyDJ 記載曾接替為天然蝦紅素及化妝保養品總代理，銷售地區包含台灣、中國大陸、東協；未上市。
  • 萊芙雅國際貿易（深圳）有限公司 MoneyDJ 記載曾與代理商簽署合作協議，屬中國大陸通路合作方，非台股掛牌；此為歷史資料。
  • 日本大型藥廠 MoneyDJ 記載聿新科天然蝦紅素曾獲日本大型藥廠採購作為阿茲海默症與心血管用藥原料，但未揭露公司名稱，無法確認是否仍持續。

Competitors

Sources（16）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.